Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017, Article ID 9712536, 8 pages
https://doi.org/10.1155/2017/9712536
Research Article

Increased Levels of Oxidative Stress Markers, Soluble CD40 Ligand, and Carotid Intima-Media Thickness Reflect Acceleration of Atherosclerosis in Male Patients with Ankylosing Spondylitis in Active Phase and without the Classical Cardiovascular Risk Factors

1School of Medicine with the Division of Dentistry in Zabrze, Department of Internal Medicine, Angiology and Physical Medicine, Medical University of Silesia, Batorego St., 15, 41-902 Bytom, Poland
2Department of Medical Physics, Chelkowski Institute of Physics, University of Silesia, 4 Uniwersytecka St., 40-007 Katowice, Poland
3School of Medicine with the Division of Dentistry in Zabrze, Department of Biochemistry, Medical University of Silesia, Jordana 19 St., 41-808 Zabrze, Poland
4School of Health Sciences in Katowice, Department of Physical Medicine, Chair of Physiotherapy, Medical University of Silesia, Medyków St., 12, 40-752 Katowice, Poland

Correspondence should be addressed to Agata Stanek; lp.nelt@kenatsa

Received 15 June 2017; Accepted 12 July 2017; Published 14 August 2017

Academic Editor: Adrian Doroszko

Copyright © 2017 Agata Stanek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Braun and J. Sieper, “Ankylosing spondylitis,” Lancet, vol. 369, no. 9570, pp. 1379–1390, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. L. E. Dean, G. T. Jones, A. G. MacDonald, C. Downham, R. D. Sturrock, and G. J. Macfarlane, “Global prevalence of ankylosing spondylitis,” Rheumatology, vol. 53, no. 4, pp. 650–657, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Han, D. W. Robinson, M. V. Hackett, L. C. Paramore, K. H. Fraeman, and M. V. Bala, “Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis,” Journal of Rheumatology, vol. 33, no. 4, pp. 2167–2172, 2006. View at Google Scholar
  4. N. Bodnár, G. Kerekes, I. Seres et al., “Assessment of sublinical vascular disease associated with ankylosing spondylitis,” The Journal of Rheumatology, vol. 38, no. 4, pp. 723–729, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Libby, P. M. Ridker, and G. K. Hansson, “Inflammation in atherosclerosis: from pathophysiology to practice,” Journal of the American College of Cardiology, vol. 54, no. 23, pp. 2129–2138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Ross, “Atherosclerosis: an inflammatory disease,” New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. B. V. Kural, A. Orem, G. Cimşit, Y. E. Yandi, and M. Calapoglu, “Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis,” Clinica Chimica Acta, vol. 328, no. 1-2, pp. 71–82, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Vogiatzi, D. Tousoulis, and C. Stefanadis, “The role of oxidative stress in atherosclerosis,” Hellenic Journal of Cardiology, vol. 50, no. 5, pp. 402–409, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. B. H. Hahn, J. Grossman, W. Chen, and M. McMahon, “The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia,” Journal of Autoimmunity, vol. 28, no. 2-3, pp. 69–75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Galkina and K. Ley, “Immune and inflammatory mechanisms of atherosclerosis,” Annual Review of Immunology, vol. 27, pp. 165–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Matsuura, L. R. Lopez, Y. Shoenfeld, and P. R. Ames, “β2-glycoprotein I and oxidative inflammation in early atherogenesis: a progression from innate to adaptive immunity?” Autoimmunity Reviews, vol. 12, no. 2, pp. 241–249, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Puurunen, M. Mänttäri, V. Manninen et al., “Antibody against oxidized low density lipoprotein predicting myocardial infarction,” Archives of Internal Medicine, vol. 154, no. 22, pp. 2605–2609, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Maggi, G. Finardi, M. Poli et al., “Specificity autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk,” Coronary Artery Disease, vol. 4, no. 12, pp. 1119–11122, 1993. View at Google Scholar
  14. J. Balla, M. T. Magyar, D. Bereczki et al., “Serum levels of platelet released CD40 ligand are increased in early onset occlusive carotid artery disease,” Disease Markers, vol. 22, no. 3, pp. 133–140, 2006. View at Publisher · View at Google Scholar
  15. M. Yuan, H. Fu, L. Ren, H. Wang, and W. Guo, “Soluble CD40 ligand promotes macrophage foam cell formation in the etiology of atherosclerosis,” Cardiology, vol. 131, no. 1, pp. 11-12, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Pervanidou, G. Chouliaras, A. Akalestos et al., “Increased placental growth factor (PlGF) concentrations in children and adolescents with obesity and the metabolic syndrome,” Hormones, vol. 13, no. 3, pp. 369–374, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Roncal, I. Buysschaert, N. Gerdes et al., “Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions,” Cardiovascular Research, vol. 86, no. 1, pp. 29–36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Lund, Q. P. Qin, T. Ilva et al., “Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation,” Circulation, vol. 108, no. 16, pp. 1924–1926, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Mueller, B. Dieplinger, W. Poelz, and M. Haltmayer, “Increased pregnancy-associated plasma protein-a as a marker for peripheral atherosclerosis: results from the Linz peripheral arterial disease study,” Clinical Chemistry, vol. 52, no. 6, pp. 1096–1103, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Karakoc, O. Altindag, K. Keles, N. Soran, and S. Selek, “Serum oxidative-antioxidative status in patients with ankylosing sponydilitis,” Rheumatolology International, vol. 27, no. 12, pp. 1131–1134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. L. D. Kozaci, I. Sari, A. Alacacioglu, S. Akar, and N. Akkoc, “Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor,” Modern Rheumatology, vol. 20, no. 1, pp. 34–39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Ozgocmen, S. Sogut, O. Ardicoglu, E. Fadillioglu, I. Pekkutucu, and O. Akyol, “Serum nitric oxide, catalase, superoxide dismutase, and malondialdehyde status in patients with ankylosing spondylitis,” Rheumatology International, vol. 24, no. 2, pp. 80–83, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Solmaz, D. Kozacı, İ. Sarı et al., “Oxidative stress and related factors in patients with ankylosing spondylitis,” European Journal of Rheumatology, vol. 3, no. 1, pp. 20–24, 2016. View at Publisher · View at Google Scholar
  24. A. Stanek, G. Cieślar, E. Romuk et al., “Decrease in antioxidant status in patients with ankylosing spondylitis,” Clinical Biochemistry, vol. 43, no. 6, pp. 565–570, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. S. van der Linden, H. A. Valkenburg, and A. Cats, “Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria,” Arthritis Rheumatology, vol. 27, no. 4, pp. 361–368, 1984. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Oyanagui, “Revaluation of assay methods and establishment of kit for superoxide dismutase activity,” Analytical Biochemistry, vol. 142, no. 2, pp. 290–296, 1984. View at Google Scholar
  27. H. Aebi, “Catalase in vitro,” Methods in Enzymology, vol. 105, pp. 121–126, 1984. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Paglia and W. Valentine, “Studies of the quantities and qualitative characterization of erythrocyte glutathione peroxidase,” Journal of Laboratory and Clinical Medicine, vol. 70, no. 1, pp. 158–169, 1967. View at Google Scholar
  29. R. Richterich, Clinical Chemistry: Theory and Practice, Academic Press, New York, 1969.
  30. I. F. F. Benzie and J. J. Strain, “The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay,” Analytical Biochemistry, vol. 239, no. 1, pp. 70–76, 1996. View at Publisher · View at Google Scholar · View at Scopus
  31. J. F. Koster, P. Biemond, and A. J. Swaak, “Intracellular and extracellular sulphydryl levels in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 45, no. 1, pp. 44–46, 1986. View at Publisher · View at Google Scholar
  32. Y. Zhao, X. Yang, W. Lu, H. Liao, and F. Liao, “Uricase based methods for determination of uric acid in serum,” Microchimica Acta, vol. 164, no. 1, pp. 1–6, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Ohkawa, N. Ohishi, and K. Yagi, “Assay for peroxides in animal tissue by thiobarbituric acid reaction,” Analytical Biochemistry, vol. 95, no. 2, pp. 351–358, 1979. View at Publisher · View at Google Scholar · View at Scopus
  34. O. Erel, “A new automated colorimetric method for measuring total oxidant status,” Clinical Biochemistry, vol. 38, no. 12, pp. 1103–1111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Garrett, T. Jenkinson, L. G. Kennedy, H. Whitelock, P. Gaisford, and A. Calin, “A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index,” Journal of Rheumatology, vol. 21, no. 12, pp. 2286–2291, 1994. View at Google Scholar
  36. A. Calin, S. Garrett, H. Whitelock et al., “A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index,” The Journal of Rheumatology, vol. 21, no. 12, pp. 2281–2285, 1984. View at Google Scholar
  37. O. V. Mitrofanova, V. V. Bagirova, and S. I. Krasikov, “Levels of lipid peroxidation products and activity of antiradical defense enzymes in blood of patients with Bechterew disease,” Terapevtichesky Arkhiv, vol. 74, no. 5, pp. 66–69, 2002. View at Google Scholar
  38. M. Nazıroğlu, S. Akkuş, and H. Celik, “Levels of lipid peroxidation and antioxidant vitamins in plasma and erythrocytes of patients with ankylosing spondylitis,” Clinical Biochemistry, vol. 44, no. 17-18, pp. 1412–1415, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Agca, S. C. Heslinga, V. P. van Halm, and M. T. Nurmohamed, “Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders,” Heart, vol. 102, no. 10, pp. 790–795, 2016. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Eriksson, L. Jacobsson, K. Bengtsson, and J. Askling, “Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?” Annals of the Rheumatic Diseases, vol. 76, no. 2, pp. 364–370, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. S. C. Heslinga, I. A. Oever, A. M. Sijl et al., “Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation,” BioMed Central Musculoskeletal Disorders, vol. 16, no. 80, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Bremander, I. F. Petersson, S. Bergman, and M. Englund, “Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis,” Arthritis Care & Research, vol. 63, no. 4, pp. 550–556, 2011. View at Publisher · View at Google Scholar
  43. S. Mathieu, L. Gossec, M. Dougados, and M. Soubrier, “Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis,” Arthritis Care & Research, vol. 63, no. 4, pp. 557–563, 2011. View at Publisher · View at Google Scholar
  44. V. P. Halm, J. C. Denderen, M. J. Peters et al., “Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 65, no. 11, pp. 1473–1477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Kucuk, A. Uğur Uslu, A. Icli et al., “The LDL/HDL ratio and atherosclerosis in ankylosing spondylitis,” Zeitschrift für Rheumatologie, vol. 76, no. 1, pp. 58–63, 2016. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Cordero, E. Andrés, B. Ordoñez et al., “The trigliceryde/high-density lipoprotein cholesterol ratio for predicting the first coronary event in men,” American Journal of Cardiology, vol. 104, no. 10, pp. 1393–1397, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. E. M. Urbina, P. R. Khoury, C. E. McCoy, L. M. Dolan, S. R. Daniels, and T. R. Kimball, “Triglyceride to HDL-C ratio and increased arterial stiffness in children, adolescents, and young adults,” Pediatrics, vol. 131, no. 4, pp. e1082–e1090, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Steinberg, “Low density lipoprotein oxidation and its pathological significance,” Journal of Biological Chemistry, vol. 272, no. 34, pp. 20963–20966, 1997. View at Google Scholar
  49. L. E. Schreier, H. Mosso, G. I. Lopez, L. Siri, and R. W. Wikinski, “Low density lipoprotein composition and oxidability in atherosclerotic cardiovascular disease,” Clinical Chemistry, vol. 29, no. 5, pp. 479–487, 1999. View at Google Scholar
  50. H. Esterbauer, R. J. Schaur, and J. Zollner, “Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes,” Free Radical Biology and Medicine, vol. 11, no. 1, pp. 81–128, 1991. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Ayala, M. F. Muroz, and S. Arguelles, “Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 360438, 31 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Esterbauer, “Cytotoxicity and genotoxicity of lipid-oxidation products,” American Journal of Clinical Nutrition, vol. 57, 5 Supplement, pp. 779S–786S, 1993. View at Google Scholar
  53. L. Paimela, T. Helve, M. Leirisalo-Repo et al., “Clinical significance of antibidies against oxidized low density lipoprotein in early RA,” Annals of the Rheumatic Diseases, vol. 55, no. 8, pp. 558-559, 1996. View at Google Scholar